Contrasting INmune Bio (NASDAQ:INMB) & Crescent Biopharma (NASDAQ:CBIO)

Crescent Biopharma (NASDAQ:CBIO) and INmune Bio (NASDAQ:INMB) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings for Crescent Biopharma and INmune Bio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1	1	2	2	2.83
INmune Bio	1	0	0	1	2.50

Crescent Biopharma currently has a consensus target price of $29.60, indicating a potential upside of 52.50%. Given Crescent Biopharma’s stronger consensus rating and higher possible upside, equities analysts plainly believe Crescent Biopharma is more favorable than INmune Bio.

Profitability

This table compares Crescent Biopharma and INmune Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-101.50%	-86.86%
INmune Bio	N/A	-82.87%	-62.23%

Institutional & Insider Ownership

75.2% of Crescent Biopharma shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 24.8% of Crescent Biopharma shares are held by company insiders. Comparatively, 21.4% of INmune Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Crescent Biopharma and INmune Bio”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84 million	66.50	-$153.94 million	($6.72)	-2.89
INmune Bio	$50,000.00	1,232.10	-$45.93 million	($0.67)	-3.31

INmune Bio has lower revenue, but higher earnings than Crescent Biopharma. INmune Bio is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Crescent Biopharma has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, INmune Bio has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500.

Summary

Crescent Biopharma beats INmune Bio on 9 of the 14 factors compared between the two stocks.

About Crescent Biopharma

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

About INmune Bio

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.